RECOVER-TLC seeks input on planned study of possible Long COVID treatment

RECOVER-TLC wants to collect feedback on this planned clinical trial in the form of public comments on the draft SGB Protocol Synopsis. This draft protocol synopsis (brief summary) contains information about the questions the study will investigate, how researchers will look for answers, and who can join the study. The draft SGB Protocol Synopsis and comment submission form will be made available on the RECOVER-TLC Collaborator Portal on February 23 and will remain accessible for 2 weeks, closing on March 8 at 11:59 pm ET.

SGB is a medical procedure during which a doctor injects a numbing medicine (anesthetic) in the stellate ganglion, which is a collection of nerves located at the bottom the neck. The stellate ganglion helps control several autonomic functions, which are bodily activities that happen without a person thinking about them, like the beating of the heart, breathing, and sweating. The purpose of this trial is to determine whether numbing the stellate ganglion helps improves quality of life and other Long COVID symptoms in people 18 years of age or older.

Comments should address the SGB trial’s feasibility (how likely it is the study will produce valuable results), accessibility (how easy it will be for people affected by Long COVID to participate in the study), and how well the trial’s design reflects the Long COVID community’s needs and priorities. 

Anyone who does not have an account and would like to become a public commenter can register through the RECOVER-TLC Collaborator Portal. Anyone who would like to comment and is already registered will not need to register again. All registered portal users will receive an email once the protocol synopsis is available for public comment.